MedTrace Logo

UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder

NCT03933410 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-01-25

No results posted yet for this study

Summary

UNLOCKED: A Phase 2 Trial to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care

Conditions

  • Urea Cycle Disorder

Interventions

DRUG

KB195

KB195 is a novel glycan

Sponsors & Collaborators

  • Kaleido Biosciences

    lead INDUSTRY

Principal Investigators

  • Mark Wingertzahn, PhD · Kaleido Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2021-02-02
Completion
2021-03-02
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Germany
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03933410 on ClinicalTrials.gov